- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Total revenues decrease 7%; Product & license revenues increase 29%; Adjusted EBITDA excluding litigation improves $0.8 million
Luna Innovations Incorporated (NASDAQ: LUNA), a company focusing on sensing, instrumentation and nanotechnology, today announced its financial results for the first quarter ended March 31, 2010.
As compared to the same quarter last year, product and license revenue increased by 29%, from $1.6 million in the first quarter of 2009 to $2.1 million in the first quarter of 2010, while total revenue decreased by 7%, from $8.5 million in the first quarter of 2009 to $7.9 million in the first quarter of 2010. The decrease in total revenue was largely the result of lower pass-through costs for subcontracts and materials under a research contract in the company's technology development business segment. Gross profit increased from $2.7 million for the first quarter of 2009 to $2.8 million for the first quarter of 2010. The company reported a net loss attributable to common shareholders of $1.3 million, or $0.10 per common share, for the first quarter of 2010, as compared to a net loss of $40.9 million, or $3.66 per common share for the first quarter of 2009. The net loss for the first quarter of 2009 included one-time charges of $36.3 million for a litigation reserve and $1.3 million for the impairment of intangible assets, and a $0.6 million charge related to the valuation allowance provided against the company's deferred tax asset. Adjusted EBITDA, which is earnings before interest, taxes, depreciation and amortization, excluding non-cash stock-based compensation expense, non-cash charges for impairment of intangible assets and charges related to the company's litigation with Hansen Medical, Inc. and its Chapter 11 reorganization, improved to positive $0.5 million for the first quarter of 2010, as compared to negative $0.3 million for the first quarter of 2009. The company consummated a settlement of its litigation with Hansen and emerged from Chapter 11 reorganization in January 2010.
Kent Murphy, Chief Executive Officer, provided this overview of Luna's results: "I am very pleased with our results since emerging from Chapter 11 reorganization in January. Recovery in demand for our fiber optic equipment during the quarter, along with our continued focus on operating expenses, has resulted in significant improvement in our core operating results that we believe represent progress toward profitability."
First Quarter Financial Highlights
-- Total revenues decreased by 7%, from $8.5 million for the first quarter of 2009 to $7.9 million for the first quarter of 2010.
-- Product and license revenues increased by 29% to approximately $2.1 million for the first quarter of 2010 from $1.6 million for the first quarter of 2009. Technology development revenues decreased by 16% to $5.8 million for the first quarter of 2010 from $6.9 million for the first quarter of 2009, primarily due to lower pass-through costs included in 2010 revenues.
-- Gross profit for the first quarter of 2010 increased to $2.8 million, or 36% of total revenues, from $2.7 million, or 32% of total revenues, for the corresponding period of 2009.
-- Selling, general and administrative expenses decreased by 19% to $3.4 million, or 43% of total revenues for the first quarter of 2010, from $4.2 million, or 50% of total revenues, for the first quarter of 2009.
-- Total operating expenses, excluding litigation and reorganization costs, decreased to $3.5 million, or 45% of total revenues for the first quarter of 2010, from $4.4 million, or 52% of total revenues, for the first quarter of 2009.
-- Adjusted EBITDA excluding litigation and bankruptcy related items increased to $0.5 million in the first quarter of 2010 from negative $0.3 million in the first quarter of 2009.
-- Net loss improved to $1.3 million for the first quarter of 2010, compared to a net loss of $40.9 million for the first quarter of 2009, primarily driven by reductions in amounts accrued with respect to the Hansen litigation in 2009 as well as expenses recognized with respect to impairment of intangible assets and the valuation of deferred tax assets as of March 2009.
-- Cash and cash equivalents totaled $6.5 million at March 31, 2010, as compared to $13.2 million at March 31, 2009. The company executed a revolving line of credit providing up to $5 million in borrowing capacity. At March 31, 2010, $2.5 million was outstanding under the line of credit.
First Quarter Business Highlights
-- The company emerged from Chapter 11 reorganization on January 12, 2010 with a court approved reorganization plan that provided for payment of 100% of valid claims and allowed stockholders to retain their equity shares.
-- The first Optical Vector Analyzer(TM) (OVA) 5000 products were shipped to customers. The OVA 5000 is a device for single-measurement, all-parameter analysis of fiber optic components and assemblies.
-- Luna began work under the development and supply agreement with Hansen Medical, entered into as part of the litigation settlement, pursuant to which Luna is integrating its fiber optic shape sensing technology into Hansen's medical robotic instruments.
-- Luna's technology development division was awarded 12 contracts in the first quarter, including eight Phase Is, two Phase 2s, one option to continue a contract and one subcontract on a Phase I.
Based on information as of May 11, 2010, the company continues to expect total revenue for 2010 to be in the range of $35.5 million to $38.0 million, consisting of product and license revenue of $9.5 million to $11.0 million and technology development revenue of $26.0 million to $27.0 million. Also for 2010, the company anticipates a GAAP net loss in the range of $2.8 million to $3.5 million, with positive adjusted EBITDA of $2.4 million to $3.9 million. For the second quarter of 2010, the company expects revenue of approximately $8.5 million to $9.5 million and a net loss of approximately $0.5 million to $1.0 million.
In evaluating the operating performance of its business, Luna's management excludes certain charges and credits that are required by generally accepted accounting principles ("GAAP"). These non-GAAP results provide useful information to both management and investors by excluding items that the company believes may not be indicative of its operating performance, because either they are unusual and the company does not expect them to recur in the ordinary course of its business or they are unrelated to the ongoing operation of the business in the ordinary course. These non-GAAP measures should be considered in addition to results and guidance prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. The non-GAAP measures included in this press release have been reconciled to the nearest GAAP measure in the table following the financial statements attached to this press release.
Conference Call Information
As previously announced, Luna Innovations will conduct an investor conference call at 5:00 p.m. (ET) today to discuss its financial results and business developments for the first quarter of 2010. The call can be accessed by dialing 866.383.8003 domestically or 617.597.5330 internationally prior to the start of the call. The access code is 33764338. Investors are advised to dial in at least five minutes prior to the call to register. The conference call will also be webcast live over the Internet. The webcast can be accessed by logging on to the "Investor Relations" section of the Luna Innovations website, www.lunainnovations.com, prior to the event. The webcast will be archived under the "Webcasts and Presentations" section of the Luna Innovations website for at least 30 days following the conference call.
To review the Consolidated Statements of Operations visit:
Forward Looking Statements:
The statements in this release that are not historical facts constitute "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include our expectations regarding financial results for the second quarter and full year 2010 and the Company's future profitability. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of the Company may differ materially from the future results, performance, and/or achievements expressed or implied by these forward-looking statements as a result of a number of factors. These factors include, without limitation the fact that the outlook for the second quarter of and full year 2010 could change, and also include, without limitations, those risks and uncertainties set forth in the Company's periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC's website at www.sec.gov. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.
About Luna Innovations Incorporated
Luna Innovations Incorporated (www.lunainnovations.com) is focused on sensing and instrumentation, and pharmaceutical nanomedicines. Luna develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. The company's products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.
For more information, please click here
Luna Innovations Incorporated
Copyright © Luna Innovations IncorporatedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016